haloperidol has been researched along with As If Personality in 21 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Excerpt | Relevance | Reference |
---|---|---|
"The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 7.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
"The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 3.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
"Haloperidol was superior to both amitriptyline and placebo on a composite measure of overall symptom severity, with no difference between amitriptyline and placebo." | 2.66 | Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. ( George, A; Nathan, RS; Perel, JM; Schulz, PM; Soloff, PH; Ulrich, RF, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 16 (76.19) | 18.7374 |
1990's | 4 (19.05) | 18.2507 |
2000's | 1 (4.76) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Machida, N | 1 |
Shiotsuka, S | 1 |
Semba, J | 1 |
Conn, LM | 1 |
Lion, JR | 1 |
Serban, G | 1 |
Siegel, S | 1 |
Garbutt, JC | 2 |
Loosen, PT | 2 |
Berman, AL | 1 |
Jordan, J | 1 |
Heinz, P | 1 |
Rao, KA | 1 |
Adlakha, A | 1 |
Meloy, T | 1 |
Soloff, PH | 3 |
George, A | 3 |
Nathan, S | 1 |
Schulz, PM | 3 |
Cornelius, JR | 1 |
Herring, J | 1 |
Perel, JM | 3 |
Gunderson, JG | 1 |
Kadysheva, NM | 1 |
Mokhovikov, AN | 1 |
Mosketi, KV | 1 |
Kryzhanovskiĭ, GN | 1 |
Glenn, M | 1 |
Nathan, RS | 2 |
Ulrich, RF | 1 |
Rockland, LH | 1 |
Valenstein, M | 1 |
Maltbie, A | 1 |
Kaplan, P | 1 |
Leonard, DP | 1 |
Kidson, MA | 1 |
Shannon, PJ | 1 |
Brown, J | 1 |
James, N | 1 |
Voelkel, A | 1 |
Wong, GH | 1 |
Cock, RJ | 1 |
Radzuweit, H | 1 |
Knorr, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
Intervention | change in score on a scale (Mean) |
---|---|
Placebo | -2.41 |
Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
Intervention | change in score on a scale (Mean) |
---|---|
Placebo | -2.09 |
Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 76.53 | 68.13 |
Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 40.90 | 29.15 |
Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 1.15 | 0.23 |
Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 28.89 | 30.75 |
Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
Intervention | score on a scale (Mean) | |
---|---|---|
Visit 1 | Visit 8 | |
Placebo | 26.17 | 20.25 |
Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
1 review available for haloperidol and As If Personality
Article | Year |
---|---|
Pharmacologic approaches to violence.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Be | 1984 |
9 trials available for haloperidol and As If Personality
Article | Year |
---|---|
Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.
Topics: Adult; Borderline Personality Disorder; Clinical Trials as Topic; Double-Blind Method; Female; Follo | 1984 |
A dramatic behavioral response to thyrotropin-releasing hormone following low-dose neuroleptics.
Topics: Adult; Borderline Personality Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1984 |
Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.
Topics: Amitriptyline; Borderline Personality Disorder; Depressive Disorder; Follow-Up Studies; Haloperidol; | 1989 |
Pharmacotherapy for patients with borderline personality disorder.
Topics: Amitriptyline; Antipsychotic Agents; Borderline Personality Disorder; Clinical Trials as Topic; Doub | 1986 |
Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.
Topics: Adolescent; Adult; Amitriptyline; Borderline Personality Disorder; Clinical Trials as Topic; Double- | 1986 |
Paradoxical effects of amitriptyline on borderline patients.
Topics: Aggression; Amitriptyline; Borderline Personality Disorder; Clinical Trials as Topic; Double-Blind M | 1986 |
Effect of tranquilizers on borderline and schizotypal patients questioned.
Topics: Borderline Personality Disorder; Clinical Trials as Topic; Haloperidol; Humans; Personality Disorder | 1985 |
Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea.
Topics: Behavior; Carbonates; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Haloperid | 1974 |
Long-term effects of haloperidol on severely emotionally disturbed children.
Topics: Affective Symptoms; Child; Child Behavior Disorders; Clinical Trials as Topic; Female; Haloperidol; | 1971 |
11 other studies available for haloperidol and As If Personality
Article | Year |
---|---|
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
The transition from inpatient to outpatient care.
Topics: Adult; Combined Modality Therapy; Conversion Disorder; Disability Evaluation; Haloperidol; Humans; I | 1994 |
Use of a revised version of the psychotropic medication efficacy graph.
Topics: Adult; Alprazolam; Haloperidol; Humans; Intellectual Disability; Male; Neurocognitive Disorders; Per | 1994 |
[Accidental intravenous administration of haloperidol decanoate].
Topics: Adult; Antipsychotic Agents; Crisis Intervention; Female; Haloperidol; Humans; Injections, Intraveno | 1996 |
Tremor, confusion, and autonomic dysfunction in Down syndrome.
Topics: Adult; Autonomic Nervous System Diseases; Confusion; Diagnosis, Differential; Down Syndrome; Haloper | 1992 |
[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia].
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; | 1988 |
Lack of effect of dopamine receptor blockade on the TSH response to TRH in borderline personality disorder.
Topics: Adult; Borderline Personality Disorder; Female; Haloperidol; Humans; Male; Personality Disorders; Re | 1987 |
Catatonia in the emergency department.
Topics: Adult; Aged; Bipolar Disorder; Catatonia; Diagnosis, Differential; Emergency Service, Hospital; Halo | 1985 |
Letter: Haloperidol.
Topics: Adult; Bipolar Disorder; Haloperidol; Humans; Male; Personality Disorders | 1973 |
[On the prophylactic treatment of cyclothymic diseases with a carboanhydrase inhibitor (author's transl)].
Topics: Acetazolamide; Amitriptyline; Aortic Valve Stenosis; Carbonic Anhydrase Inhibitors; Haloperidol; Hea | 1973 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |